<- Go Home
Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. It also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Market Cap
$349.1M
Volume
N/A
Cash and Equivalents
$69.4M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$13.50
52 Week Low
$6.57
Dividend
N/A
Price / Book Value
-1.33
Price / Earnings
-0.57
Price / Tangible Book Value
-1.33
Enterprise Value
$387.3M
Enterprise Value / EBITDA
N/A
Operating Income
-$64.5M
Return on Equity
N/A
Return on Assets
N/A
Cash and Short Term Investments
$69.4M
Debt
$107.6M
Equity
-$46.8M
Revenue
N/A
Unlevered FCF
N/A
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium